Eslin D, Zage PE, Bergendahl G, Lewis E, et al. A phase II trial of nifurtimox combined with topotecan and cyclophosphamide for refractory or relapsed neuroblastoma and medulloblastoma. Int J Cancer 2023 May 29. doi: 10.1002/ijc.34569.
PMID: 37246577